Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Thiele J, Kvasnicka HM.

Curr Hematol Malig Rep. 2009 Jan;4(1):33-40. doi: 10.1007/s11899-009-0005-6.

PMID:
20425436
2.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
3.

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al.

Neth J Med. 1999 Feb;54(2):46-62. Review.

PMID:
10079679
4.

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Barbui T, Thiele J, Vannucchi AM, Tefferi A.

Blood Cancer J. 2015 Aug 14;5:e337. doi: 10.1038/bcj.2015.64. Review.

6.
7.

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].

Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.

Vnitr Lek. 2011 Feb;57(2):189-213. Review. Czech.

PMID:
21416861
8.
9.

WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.

Michiels JJ, De Raeve H, Hebeda K, Lam KH, Berneman Z, Schroyens W, Schwarz J.

Leuk Res. 2007 Aug;31(8):1031-8. Epub 2007 Mar 23. Review.

PMID:
17367853
10.

Prodromal myeloproliferative neoplasms: the 2008 WHO classification.

Kvasnicka HM, Thiele J.

Am J Hematol. 2010 Jan;85(1):62-9. doi: 10.1002/ajh.21543. Review.

11.
13.

The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.

Spivak JL, Silver RT.

Blood. 2008 Jul 15;112(2):231-9. doi: 10.1182/blood-2007-12-128454. Epub 2008 Apr 9. Review. No abstract available.

14.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
15.

Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.

Barosi G.

Best Pract Res Clin Haematol. 2014 Jun;27(2):129-40. doi: 10.1016/j.beha.2014.07.004. Epub 2014 Jul 18. Review.

PMID:
25189724
16.

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T.

Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):849.

17.

A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.

Thiele J, Kvasnicka HM.

Leuk Lymphoma. 2006 Mar;47(3):381-96. Review.

PMID:
16396760
18.
19.

Molecular genetic evaluation of myeloproliferative neoplasms.

Azzato EM, Bagg A.

Int J Lab Hematol. 2015 May;37 Suppl 1:61-71. doi: 10.1111/ijlh.12353. Review.

PMID:
25976962

Supplemental Content

Support Center